Pulmonx Corp (OQ:LUNG)

May 06, 2024 05:03 pm ET
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”)...
May 01, 2024 04:05 pm ET
Pulmonx Reports First Quarter 2024 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Recorded worldwide...
Apr 10, 2024 04:05 pm ET
Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1,...
Apr 02, 2024 04:05 pm ET
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John...
Mar 15, 2024 05:00 pm ET
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President and Chief...
Feb 26, 2024 08:00 am ET
Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the treatment of the first patient in the CONVERT II Pivotal Trial, a multicenter, international study evaluating the safety and effectiveness of the AeriSeal® System in limiting collateral ventilation in severe COPD/emphysema patients. Collateral ventilation is caused by openings in the lung fissures, or walls between the lung lobes. The AeriSeal System is designed to occlude these naturally occurring ope
Feb 21, 2024 04:06 pm ET
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2023 ended December 31, 2023. Recent...
Feb 21, 2024 04:05 pm ET
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company’s President and Chief Executive Officer, effective March...
Feb 07, 2024 04:05 pm ET
Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2023 after the close of trading on...
Dec 11, 2023 09:00 am ET
The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors
The Honest Company (NASDAQ: HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael...
Nov 15, 2023 04:05 pm ET
Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in...
Oct 31, 2023 04:05 pm ET
Pulmonx to Participate at Upcoming Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to...
Oct 30, 2023 04:05 pm ET
Pulmonx Reports Record Third Quarter 2023 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2023 ended September 30, 2023. Recent Highlights...
Oct 16, 2023 04:05 pm ET
Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Monday, October...
Oct 10, 2023 04:05 pm ET
Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Derrick Sung has stepped down from his position as Chief Financial Officer to pursue another...
Aug 30, 2023 04:05 pm ET
Pulmonx to Participate at Upcoming Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to...
Aug 02, 2023 04:05 pm ET
Pulmonx Reports Second Quarter 2023 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights...
Jul 26, 2023 04:05 pm ET
Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston. Management...
Jul 17, 2023 08:00 am ET
Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Wednesday, August...
May 02, 2023 04:05 pm ET
Pulmonx Reports First Quarter 2023 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023. Recent Highlights...
Apr 25, 2023 04:05 pm ET
Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2023 Health Care Conference in Las Vegas on...
Apr 18, 2023 04:05 pm ET
Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May 2, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Feb 22, 2023 04:05 pm ET
Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022. Recent...
Feb 16, 2023 04:05 pm ET
Pulmonx to Present at the Citi 2023 Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2023 Healthcare Conference in New York on...
Feb 08, 2023 04:05 pm ET
Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on...
Dec 14, 2022 04:05 pm ET
American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, has partnered with American Lung Association to provide education to patients and providers on Endobronchial Valves, a clinically proven treatment to help people with severe COPD/emphysema breathe easier.1 COPD has no cure and is the third leading cause of death worldwide. Individuals living with advanced disease often struggle with each breath and have a very poor quality of life, and traditionally have not had good treatment options once medication alone no lon
Nov 30, 2022 07:00 am ET
Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr® Endobronchial Valve for treating severe COPD/emphysema patients following a positive recommendation by Pharmaceuticals and Medical Devices Agency (PMDA). The Zephyr Valve is a minimally invasive treatment option that can deliver significant benefits to patients including improvements in lung function, exercise capacity, and quality of life.1 Placed
Nov 16, 2022 04:05 pm ET
Pulmonx to Present at the 34th Annual Piper Sandler Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference in...
Nov 04, 2022 08:00 am ET
Pulmonx to Participate at Upcoming Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences in New York. Pulmonx management is...
Nov 03, 2022 04:05 pm ET
Pulmonx Reports Third Quarter 2022 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Achieved...
Oct 20, 2022 04:05 pm ET
Pulmonx to Report Third Quarter 2022 Financial Results on November 3, 2022
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November...
Sep 09, 2022 03:29 pm ET
Sep 04, 2022 06:15 am ET
CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the presentation of interim results from the CONVERT Study at the 2022 European Respiratory Society (ERS) International Conference. Data on the first 40 patients in the study demonstrated that treatment with the AeriSeal System successfully converted the collateral ventilation (CV) status in 78% of patients who were subsequently treated with Zephyr Valves.
Aug 24, 2022 04:05 pm ET
Pulmonx to Present at Upcoming September Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in fireside chats at two upcoming investor conferences. Pulmonx management is scheduled to participate in the 2022 Wells Fargo Healthcare Conference in Boston on Wednesday, September 7, 2022, at 6:10am PT / 9:10am ET and the Morgan Stanley 20th Annual Global Healthcare Conference in New York on Tuesday, September 13, 2022, at 1:40pm PT / 4:40pm ET.
Aug 02, 2022 04:05 pm ET
Pulmonx Reports Second Quarter 2022 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights...
Jul 27, 2022 04:05 pm ET
Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 10, 2022, at 1:00 PM PT / 4:00 PM ET.
Jul 19, 2022 04:05 pm ET
Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
May 03, 2022 04:05 pm ET
Pulmonx Reports First Quarter 2022 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Recorded worldwide...
Apr 26, 2022 04:05 pm ET
Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Bank of America Securities 2022 Healthcare Conference in Las Vegas....
Apr 19, 2022 04:05 pm ET
Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Tuesday, May 3,...
Feb 23, 2022 04:05 pm ET
Pulmonx Reports Fourth Quarter and Full Year 2021 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2021 ended December 31, 2021. Recent...
Feb 10, 2022 04:05 pm ET
Pulmonx to Present at the Citi 2022 Virtual Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2022 Virtual Healthcare Conference on...
Feb 09, 2022 04:05 pm ET
Pulmonx to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on...
Dec 29, 2021 04:05 pm ET
Pulmonx to Present at the 40th Annual J.P. Morgan Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference. Management is scheduled...
Nov 16, 2021 04:05 pm ET
Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will participate in the 33rd Annual Piper Sandler Healthcare Conference being held from November...
Nov 03, 2021 08:00 am ET
Pulmonx to Participate at Upcoming Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming virtual investor conferences. Pulmonx management is...
Nov 02, 2021 04:05 pm ET
Pulmonx Reports Third Quarter 2021 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the third quarter ended September 30, 2021. Recent Highlights...
Oct 26, 2021 04:05 pm ET
Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Tuesday, November...
Sep 21, 2021 04:05 pm ET
Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced that Blue Cross Blue Shield (BCBS) Michigan and Horizon BCBS have issued positive coverage policies for endobronchial valves, such as the Zephyr® Endobronchial Valve (Zephyr Valve), for severe emphysema, a form of COPD. This follows similar coverage decisions by other BCBS plans and now establishes positive coverage with the majority of BCBS covered members in the US (for an aggregate of 69 million covered lives). The Zephyr Valves are placed by b
Aug 26, 2021 04:05 pm ET
Pulmonx to Present at Upcoming September Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in fireside chats at two upcoming virtual investor conferences. Pulmonx management is scheduled to participate in the 2021 Virtual Wells Fargo...
Aug 20, 2021 04:30 pm ET
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonx’s Zephyr® Valve, for severe emphysema, a form of COPD. This follows similar coverage decisions by other BCBS plans and brings the total BCBS covered members in the US to 59 million. The Zephyr Valve has been shown to deliver significant benefits to patients with emphysema including improvements in lung function, exercise capa
Aug 03, 2021 04:05 pm ET
Pulmonx Reports Second Quarter 2021 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Achieved...
Aug 02, 2021 08:45 am ET
Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Healthcare Delivery Networks
Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive treatments for severe lung disease, welcomes Alissa Hsu Lynch and Tiffany Sullivan to its Board of Directors. Ms. Lynch will serve as a member of the Audit Committee and Ms....
Jul 29, 2021 04:05 pm ET
Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on...
Jul 27, 2021 09:14 am ET
Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long-term follow-up data of the IMPACT Study, a multi-center randomized clinical trial of the Zephyr® Valves. The IMPACT data show that Zephyr Valves deliver significant benefits to a group of severe COPD/emphysema patients that have very few treatment options because of widespread destruction of lung tissue across their lungs (also known as homogenous distribution of emphysema). The Zephyr Valve is the only endobronchial valve to receive
Jul 20, 2021 04:05 pm ET
Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August...
May 17, 2021 04:05 pm ET
Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced that key long-term follow-up data from the TRANSFORM® study was presented at the American Thoracic Society (ATS)...
May 04, 2021 04:02 pm ET
Pulmonx Reports First Quarter 2021 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 2021. Recent Highlights Reported...
May 04, 2021 04:01 pm ET
Pulmonx Corporation Expands Leadership Team
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the appointment of Michael Ryan as Vice President, Corporate Strategy and Business Development, and the earlier...
Apr 27, 2021 04:05 pm ET
Pulmonx to Present at BofA Securities 2021 Virtual Health Care Conference
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for lung disease, today announced the company will be participating in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on...
Apr 20, 2021 04:05 pm ET
Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Tuesday, May 4,...
Mar 02, 2021 04:01 pm ET
Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2020 ended December 31, 2020. Recent...
Feb 16, 2021 04:01 pm ET
Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on...
Jan 28, 2021 08:02 am ET
JTV®, Pulmonx® Corporation & Respiratory Health Association® Launch 2021 Catch Your Breath® Campaign
KNOXVILLE, Tenn., Jan. 28, 2021 /PRNewswire/ -- JTV®, the national jewelry retailer and broadcast network, is excited to announce its third annual Catch Your Breath® campaign, in partnership with Respiratory Health Association® (RHA) and co-sponsor Pulmonx® Corporation, to support the fight against women's lung disease.
Dec 08, 2020 08:13 am ET
Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth
Pulmonx Corporation (Nasdaq: LUNG), a pioneer in providing minimally invasive treatment for patients with severe lung disease, welcomes Georgia Garinois-Melenikiotou and Thomas W. Burns to its Board of Directors. Both Directors joined the Pulmonx...
Nov 30, 2020 08:00 am ET
Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
As part of COPD Awareness Month, Pulmonx Corporation is announcing that over 20,000 patients have been treated worldwide with their Zephyr® Endobronchial Valves (Zephyr Valve), the first FDA-approved minimally-invasive treatment for severe...
Nov 10, 2020 04:01 pm ET
Pulmonx Reports Third Quarter 2020 Financial Results
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a form of COPD, today reported financial results for the third quarter...
Nov 03, 2020 08:00 am ET
Pulmonx to Present at Upcoming Investor Conferences
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in two upcoming virtual investor conferences. Pulmonx management is scheduled to present at the Stifel 2020 Virtual Healthcare Conference on Monday,...
Nov 02, 2020 10:00 am ET
Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD)
Pulmonx Corporation (NASDAQ: LUNG) today announced that Health Care Service Corporation (HCSC) has issued a positive coverage policy for the Zephyr® Endobronchial Valve (Zephyr Valve) for the treatment of severe emphysema, a form of COPD. HCSC...
Oct 22, 2020 04:01 pm ET
Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2020 after the close of trading on Tuesday, November...
Oct 05, 2020 04:01 pm ET
Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced the closing of its initial public offering of 11,500,000...
Sep 30, 2020 10:36 pm ET
Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
Pulmonx Corporation (“Pulmonx”) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price of $19.00 per share, for gross proceeds of $190,000,000 million, before underwriting discounts...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.